Izalontamab clinical trials
Also written SI-B001.
How each study uses izalontamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SI-B001
- 10
Studies by the year they started
10 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test izalontamab.
- Nov 2026A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPhase 2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCPhase 2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaPhase 1/2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerPhase 1/2 · Sichuan Baili Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses izalontamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05054439Written as SI-B001How we know
- A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT05668858Written as SI-B001How we know
- A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT05949606Written as SI-B001How we know
- A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06668961Written as SI-B001How we know
- SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.Active, not recruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT05020769Written as SI-B001How we know
- A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05044897Written as SI-B001How we know
- SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Active, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05022654Written as SI-B001How we know
- A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsActive, not recruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT04603287Written as SI-B001How we know
- A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaActive, not recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT05943795Written as SI-B001How we know
- SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System MalignanciesTerminatedPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05039944Written as SI-B001How we know
Given beside what is tested · 1 — izalontamab is usual care or a partner of the new treatment
Codes
What other systems call izalontamab · ClinicalTrials.gg INT017877
- UNII (FDA) S8YH2C9NLAIZALONTAMABOne source FDA
- NCI Thesaurus C178396IzalontamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S8YH2C9NLA | IZALONTAMAB | One source FDA |
| NCI Thesaurus | C178396 | Izalontamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.